STOCK TITAN

Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Xtant Medical Holdings (XTNT) reported third-quarter 2026 revenue of $24.3 million and announced an ongoing board-led review of strategic alternatives. Revenue fell from $33.3 million a year earlier but rose 5% sequentially. The company attributed the annual decline primarily to divestitures and absent wound care licensing revenue. Biologics revenue rose 13% year over year to $19.3 million, including $2.2 million from HEMOBLAST.

Gross margin fell to 56.3% from 66.1%. Net loss was $3.6 million, or $0.03 per share, versus $1.3 million in prior-year profit. Xtant no longer expects to meet its previous full-year guidance and is not issuing revised guidance during the review. At September 30, cash was $7.8 million and debt was $22 million. The company expects cash and revolving credit availability to fund at least the next 12 months under its current operating plan. The review has no completion timetable.

Loading...
Loading translation...
9 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointBiologics revenue reached $19.3 million, up 13% year over year and 11% sequentially in Q3 2026.
  • Moderate pointGeneral and administrative expenses fell to $5.0 million in Q3 2026 from $7.1 million a year earlier.
  • Moderate pointTotal indebtedness declined to $22 million at September 30, 2026, from $25.4 million at December 31, 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Xtant expects cash and revolving credit availability to fund operations for at least the next 12 months.
  • Minor pointHEMOBLAST sales contributed $2.2 million to third-quarter 2026 revenue.
4 minor points
  • Minor pointNon-GAAP biologics product revenue excluding HEMOBLAST and wound-reimbursement-affected products grew 8% sequentially and 6% annually in Q3.
  • Minor pointSales and marketing expenses fell to $11.2 million in Q3 2026 from $11.7 million a year earlier.
  • Minor pointResearch and development expenses fell to $496,000 in Q3 2026 from $634,000 a year earlier.
  • Minor pointInterest expense fell to $590,000 in Q3 2026 from $904,000 a year earlier.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Xtant no longer expects to achieve its previous full-year 2026 guidance after two consecutive quarterly guidance misses.
  • Moderate pointQ3 2026 revenue fell to $24.3 million from $33.3 million annually, despite rising 5% sequentially.
  • Moderate pointQ3 gross margin fell to 56.3% from 66.1%, reflecting lost licensing revenue and sales mix.
  • Moderate pointQ3 2026 net loss was $3.6 million, or $0.03 per share, versus $1.3 million profit a year earlier.
  • Moderate pointQ3 adjusted EBITDA, adjusted earnings before interest, taxes, depreciation and amortization, was negative $1.5 million versus positive $4.5 million annually.
  • Moderate pointCash declined to $7.8 million at September 30, 2026, from $17.1 million at December 31, 2025.
  • Moderate pointA distribution agreement deposit write-off added $5 million to expenses in the first nine months of 2026. 13% of market cap
3 minor points
  • Minor pointRevolving credit availability declined to $2.1 million at September 30, 2026, from $3.8 million at year-end 2025.
  • Minor pointNine-month revenue fell to $68.200 million in 2026 from $101.570 million a year earlier.
  • Minor pointNine-month net loss was $16.064 million in 2026 versus $4.916 million profit a year earlier.

News Explained

The release lists 140,452,061 common shares issued and outstanding at September 30, 2026, versus 140,039,557 at December 31, 2025; the higher share count means existing holders’ percentage ownership is lower, absent offsetting changes.

Argus 15 min delay 1 alert
-4.20% vs previous close $0.2603 last price 0.0x rel. volume Open Argus
Details

Market move: XTNT -4.20% vs previous close. Q3 2026 earnings report

$0.26 – $0.27 Day Range
$36.52M Mkt Cap at Last Price

On Nov 16, the day this news came out, the latest delayed price for XTNT is 4.20% below the previous close. The latest delayed price is $0.26.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Total revenue: $24.3 million Biologics revenue: $19.3 million; up 13% year over year and 11% quarter over quarter Gross margin: 56.3% +5 more
Total revenue
$24.3 million
Q3 2026; compared with $33.3 million in Q3 2025 and $23.0 million in Q2 2026
Biologics revenue
$19.3 million; up 13% year over year and 11% quarter over quarter
Q3 2026
Gross margin
56.3%
Q3 2026, compared with 66.1% in Q3 2025
Net loss
$3.6 million
Q3 2026, compared with net income of $1.3 million in Q3 2025
Adjusted EBITDA
$1.5 million loss
Q3 2026, compared with adjusted EBITDA of $4.5 million in Q3 2025
Cash and cash equivalents
$7.8 million
As of September 30, 2026
Total indebtedness
$22 million
As of September 30, 2026
Operating funding outlook
At least 12 months
Company expects cash and revolving credit availability to fund operations under its current operating plan

Previous Earnings Reports

1 past event · Latest: Aug 11
Same Type 1 event
  1. Aug 11

    Q2 earnings

    24h Move
    -28.3%

    Revenue fell to $23.0 million and the company lowered 2026 revenue guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adjusted ebitda, non-gaap, revolving credit facility, gaap
4 terms
adjusted ebitda financial
"Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
non-gaap financial
"Adjusted EBITDA, a non-GAAP measure"
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
View in glossary
revolving credit facility financial
"$11.8 million of borrowings under its revolving credit facility"
A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.
gaap financial
"prepared in accordance with U.S. generally accepted accounting principles (GAAP)"
GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives.

BELGRADE, Mont., Nov. 16, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2026.

Xtant Medical Logo

Third Quarter 2026 Financial Highlights

  • Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of revenue from divested businesses and wound care licensing revenue.
  • Biologics revenue was $19.3 million for the third quarter of 2026, up 13% from the third quarter of 2025 and up 11% from the second quarter of 2026, third quarter 2026 revenue includes $2.2 million from sales of HEMOBLAST® Bellows.

"The Board is disappointed with Xtant's financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable," said Stavros Vizirgianakis, Chairman of the Board. "Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board's interests are directly aligned with stockholders. The Board's priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year."

The Board's active strategic review process is evaluating a broad range of potential actions to maximize stockholder value, which may include, among other things, operational and performance improvement initiatives, capital allocation and capital structure alternatives, commercial or strategic partnerships, restructurings, financings, acquisitions, dispositions, business combinations or other transactions. The Board has not set a timetable for completion of the strategic review process, and there can be no assurance that the process will result in any particular action or outcome. The Company does not intend to disclose further developments unless and until the Board approves a specific action or otherwise determines that further disclosure is appropriate or required.

Third Quarter 2026 Financial Results

Revenue for the third quarter of 2026 was $24.3 million compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of $5.4 million of prior-year revenue from the divested non-core Coflex/CoFix assets and international hardware business, and the absence of $5.5 million of prior-year wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. Biologics revenue was $19.3 million, an increase of 13% from $17.1 million for the third quarter of 2025 and 11% from $17.4 million for the second quarter of 2026. Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement, a non-GAAP measure, grew 8% compared to the second quarter of 2026 and 6% compared to the third quarter of 2025.

Gross margin for the third quarter of 2026 was 56.3%, compared to 66.1% for the same period in 2025. The decrease primarily reflected a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix.

Operating expenses for the third quarter of 2026 were $16.7 million, compared to $19.5 million for the third quarter of 2025. General and administrative expenses decreased to $5.0 million from $7.1 million, due primarily to the divested non-core Coflex/CoFix assets and international hardware business and lower expense under compensation plans. Sales and marketing expenses decreased to $11.2 million from $11.7 million due primarily to savings related to the divestitures and lower consulting fees, partially offset by higher compensation expense from increased sales headcount, including sales personnel hired in connection with the Company's exclusive U.S. distribution agreement for HEMOBLAST, and by higher independent agent commissions and travel expenses.

Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025.

Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million for the third quarter of 2026, compared to adjusted EBITDA of $4.5 million for the third quarter of 2025.

The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/ acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) is included in the financial tables at the end of this release.

As of September 30, 2026, the Company had $7.8 million of cash and cash equivalents; $22 million of total indebtedness, consisting of $10.2 million of current and long-term debt and $11.8 million of borrowings under its revolving credit facility; and $2.1 million of availability under its revolving credit facility. As of December 31, 2025, the Company had $17.1 million of cash and cash equivalents; $25.4 million of total indebtedness, consisting of $14.5 million of current and long-term debt and $10.9 million of revolving credit borrowings; and $3.8 million of revolving credit availability.

Based on its current operating plan, the Company expects its cash and cash equivalents, and availability under its revolving credit facility, to be sufficient to fund operations for at least the next 12 months.

2026 Financial Guidance

Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. While the Board of Directors conducts its strategic review process, the Company is not providing revised full-year 2026 financial guidance. At the same time, as detailed elsewhere in this release, the Board is encouraged by the recent momentum in the Company's core biologics business and remains committed to scaling this franchise throughout the strategic review process.

Conference Call

Xtant Medical will not host a conference call or webcast to discuss its third quarter 2026 financial results. 

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including EBITDA, adjusted EBITDA, EBITDA and adjusted EBITDA as a percentage of total revenue, and biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are included in the tables at the end of this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," "expects," "anticipates," "plans," "believes," "estimates," "projects," "seeks," "aims," "goal," "strategy," "continue," "future," "will," "would," "should," "could," "may," "potential," "opportunity," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include, among others, statements regarding the recent momentum in the Company's core biologics products business and the Board's commitment to scaling that business; the Board's priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; the scope, timing, conduct and potential outcomes of the strategic review process; the Company's expectation that it will not achieve its previously issued full-year 2026 guidance; the Company's expectation that its cash and cash equivalents and availability under its revolving credit facility, will be sufficient to fund operations for at least the next 12 months; and the expected timing of the filing of the Company's Quarterly Report on Form 10-Q. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results, financial performance and need for additional capital; the Company's ability to sustain or increase revenue growth in its biologics business, including the possibility that recent growth trends will not continue; results of the Board's strategic review process, including the possibility that the process will not result in any strategic alternative, operational change, restructuring, transaction, initiative or other action, or that any action taken will not achieve its anticipated benefits or enhance stockholder value; the timing of the strategic review process and the possibility that it may be suspended, modified or terminated at any time; the Company's ability to identify, negotiate, finance, obtain any required approvals for and complete any strategic alternative, operational change, transaction, partnership, restructuring or other action on favorable terms or at all, and to implement successfully its strategic priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; risks associated with the strategic review process, including disruption and distraction of management, costs, and effects on employees, agents, customers, suppliers and other business relationships; the absence of financial guidance and the Company's inability to achieve its previously issued guidance; the Company's ability to generate operating cash flows and maintain availability under its revolving credit facility; the success of the Dilon distribution arrangement and the HEMOBLAST product and the possibility that the distribution agreement may be terminated and the effect of any such termination on the Company, its business and operating results; the ability of Dilon to continue to manufacture and supply the HEMOBLAST product and the effect of any such non-performance on the Company and its business and operating results; the success of the Company's expanded field sales force to improve its reach and leverage its contract portfolio and independent agent network; other risks associated with acquisitions and dispositions; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products, including the absence of future license revenue resulting from changes in the reimbursement environment; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject, including any litigation relating to the strategic review process; the effect of product recalls and defects; its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt and comply with the covenants in its credit agreements, including the minimum liquidity and net revenue covenants, to obtain any needed future amendments or waivers, and to access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 to be filed with the SEC on or about November 16, 2026. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

XTANT MEDICAL HOLDINGS, INC.

Consolidated Balance Sheets

(In thousands, except number of shares and par value)




As of
September 30, 2026



As of

December 31, 2025




(Unaudited)





ASSETS









Current Assets:









Cash and cash equivalents


$

7,793



$

17,053


Restricted cash



92




275


Trade accounts receivable, net of allowance for credit losses and
doubtful accounts of $2,756 and $2,165, respectively



18,823




17,803


Inventories



32,503




30,263


Note receivable



—




10,462


Prepaid and other current assets



1,395




2,389


Total current assets



60,606




78,245


Property and equipment, net



5,449




6,202


Right-of-use asset, net



2,738




3,192


Goodwill



6,074




6,074


Intangible assets, net



229




299


Other assets



127




133


Total Assets


$

75,223



$

94,145











LIABILITIES & STOCKHOLDERS' EQUITY









Current Liabilities:









Accounts payable


$

5,364



$

3,844


Accrued liabilities



7,699




10,626


Current portion of long-term debt



4,770




3,500


Current portion of lease liability



588




622


Current portion of finance lease obligations



19




35


Line of credit



11,833




10,857


Total current liabilities



30,273




29,484


Long-term Liabilities:









Lease liability, less current portion



2,248




2,665


Finance lease obligation, less current portion



—




12


Long-term debt, plus premium and less issuance costs



5,436




11,026


Other liabilities



7




5


Total Liabilities



37,964




43,192


Commitments and Contingencies









Stockholders' Equity:









Preferred stock, $0.000001 par value; 10,000,000 shares
authorized; no shares issued and outstanding



—




—


Common stock, $0.000001 par value; 300,000,000 shares
authorized; 140,452,061 shares issued and outstanding as of
September 30, 2026 and 140,039,557 shares issued and
outstanding as of December 31, 2025



—




—


Additional paid-in capital



307,810




305,439


Accumulated other comprehensive loss



(1)




—


Accumulated deficit



(270,550)




(254,486)


Total Stockholders' Equity



37,259




50,953


Total Liabilities & Stockholders' Equity


$

75,223



$

94,145


 

XTANT MEDICAL HOLDINGS, INC.

Consolidated Statements of Operations

(Unaudited, in thousands, except number of shares and per share amounts)




Three Months Ended

September 30,



Nine Months Ended

September 30,




2026



2025



2026



2025


Revenue

















Product revenue


$

24,285



$

27,772



$

68,200



$

87,492


License revenue



—




5,483




—




14,078


Total Revenue



24,285




33,255




68,200




101,570



















Cost of Sales



10,623




11,263




29,237




35,051


Gross Profit



13,662




21,992




38,963




66,519



















Operating Expenses

















General and administrative



5,013




7,071




17,722




22,082


Sales and marketing



11,181




11,746




29,735




34,566


Research and development



496




634




1,626




1,643


Write-off of distribution agreement deposit



—




—




5,000




—


Total Operating Expenses



16,690




19,451




54,083




58,291



















(Loss) Income from Operations



(3,028)




2,541




(15,120)




8,228



















Other Expense

















Interest expense



(590)




(904)




(1,731)




(2,953)


Interest income



—




—




220




—


Unrealized foreign currency transaction
(loss) gain



(10)




(56)




12




146


Other income (expense)



231




(16)




820




(18)


Total Other Expense



(369)




(976)




(679)




(2,825)



















Net (Loss) Income from Operations
Before Provision for Income Taxes



(3,397)




1,565




(15,799)




5,403



















Provision for Income Taxes Current and
Deferred



(165)




(257)




(265)




(487)


Net (Loss) Income


$

(3,562)



$

1,308



$

(16,064)



$

4,916



















Net (Loss) Income Per Share:

















Basic


$

(0.03)



$

0.01



$

(0.11)



$

0.04


Diluted


$

(0.03)



$

0.01



$

(0.11)



$

0.03



















Shares used in the computation:

















Basic



140,363,595




139,712,969




140,228,117




139,366,489


Diluted



140,363,595




150,377,234




140,228,117




149,912,292


 

XTANT MEDICAL HOLDINGS, INC.

Consolidated Statements of Cash Flows

(Unaudited, in thousands)




Nine Months Ended
September 30,




2026



2025


Operating activities:









Net (loss) income


$

(16,064)



$

4,916


Adjustments to reconcile net (loss) income to net cash (used in) provided by
operating activities:









Depreciation and amortization



1,525




3,404


Loss (gain) on sale of fixed assets



—




(16)


Non-cash interest



380




415


Stock-based compensation



2,451




2,165


Provision for reserve on accounts receivable



987




568


Provision for excess and obsolete inventory



2,904




1,318


Write-off of distribution agreement deposit



5,000




—


Other



4




68











Changes in operating assets and liabilities:









Accounts receivable



(2,007)




(5,639)


Inventories



(4,215)




(2,789)


Prepaid and other assets



166




314


Accounts payable



1,519




(1,279)


Accrued liabilities



(2,927)




3,721


Net cash (used in) provided by operating activities



(10,277)




7,166











Investing activities:









Purchases of property and equipment



(830)




(1,987)


Proceeds from sale of fixed assets



129




206


Distribution agreement deposit



(5,000)




—


Proceeds from divestitures



10,368




5,000


Net cash provided by investing activities



4,667




3,219











Financing activities:









Borrowings on line of credit



51,879




77,573


Repayments on line of credit



(50,902)




(78,385)


Payments on long-term debt



(4,701)




(5,000)


Debt issuance costs



—




(49)


Payments on financing leases



(27)




(51)


Payment of taxes from withholding of common stock on settlement of restricted
stock units



(80)




(116)


Net cash used in financing activities



(3,831)




(6,028)











Effect of exchange rate changes on cash and cash equivalents and restricted cash



(2)




63











Net change in cash and cash equivalents and restricted cash



(9,443)




4,420


Cash and cash equivalents and restricted cash at beginning of period



17,328




6,221


Cash and cash equivalents and restricted cash at end of period


$

7,885



$

10,641


Reconciliation of cash and cash equivalents and restricted cash reported in the
condensed consolidated balance sheets









Cash and cash equivalents


$

7,793



$

10,400


Restricted cash



92




241


Total cash and restricted cash reported in condensed consolidated balance sheets


$

7,885



$

10,641


 

XTANT MEDICAL HOLDINGS, INC.

CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA

(in thousands)




Three Months Ended

September 30,



Nine Months Ended

September 30,




2026



2025



2026



2025



















Net (Loss) Income


$

(3,562)



$

1,308



$

(16,064)



$

4,916



















   Depreciation and amortization



483




1,161




1,525




3,404


   Interest expense, net



590




904




1,511




2,953


   Tax expense



165




257




265




487


   Non-GAAP EBITDA



(2,324)




3,630




(12,763)




11,760



















   Net (Loss) Income/Total Revenue



(14.7)

%



3.9

%



(23.6)

%



4.8

%


















   Non-GAAP EBITDA/Total Revenue



(9.6)

%



10.9

%



(18.7)

%



11.6

%


















NON-GAAP ADJUSTED EBITDA CALCULATION

















   Non-cash compensation



830




641




2,451




2,165


   Write-off of distribution agreement deposit



—




—




5,000




—


   Divestiture/acquisition-related expenses



(94)




74




(612)




369


   Acquisition-related fair value adjustments



37




140




132




311


   Unrealized foreign currency translation loss (gain)



10




56




(12)




(146)


   Separation related expenses



69




—




69




23



















   Non-GAAP Adjusted EBITDA


$

(1,472)



$

4,541



$

(5,735)



$

14,482



















   Non-GAAP Adjusted EBITDA/Total
Revenue



(6.1)

%



13.7

%



(8.4)

%



14.3

%

 

XTANT MEDICAL HOLDINGS, INC.

RECONCILIATION OF NON-GAAP BIOLOGICS PRODUCT REVENUE GROWTH

(in thousands)




Three Months Ended






 September 30,
2026


June 30,

2026


% Increase
(Decrease)


   Total Revenue


$

24,285


$

23,031





License Revenue



—



—





Hardware Revenue



4,944



5,671





   Biologics Revenue



19,341



17,360
















Sales related to HEMOBLAST and products affected by the
market for wound care reimbursement



2,204



1,518





Biologics product revenue excluding HEMOBLAST and
products affected by the market for wound care reimbursement


$

17,137


$

15,842



8

%




Three Months Ended






 September 30,
2026


September 30,
2025


% Increase
(Decrease)


   Total Revenue


$

24,285


$

33,255





License Revenue



—



5,483





Hardware Revenue



4,944



10,623





   Biologics Revenue



19,341



17,149
















Sales related to HEMOBLAST and products affected by the
market for wound care reimbursement



2,204



935





Biologics product revenue excluding HEMOBLAST and
products affected by the market for wound care reimbursement


$

17,137


$

16,214



6

%

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-reports-third-quarter-2026-financial-results-and-announces-board-led-strategic-review-process-302939954.html

SOURCE Xtant Medical Holdings, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Xtant Medical's third-quarter 2026 earnings results?

Xtant reported $24.3 million in revenue and a $3.6 million net loss, or $0.03 per share. A year earlier, revenue was $33.3 million and net income was $1.3 million, or $0.01 per diluted share.

Why does Xtant no longer expect to meet its 2026 guidance?

Xtant cited year-to-date performance as the reason it no longer expects to achieve its previously issued full-year 2026 guidance. The company is not providing revised full-year guidance while the board conducts its strategic review.

What alternatives is Xtant Medical considering in its strategic review?

The board is evaluating operational improvements, capital allocation and capital structure alternatives, alongside partnerships, restructurings, financings, acquisitions, dispositions, business combinations and other transactions. Further developments will not be disclosed unless the board approves a specific action or determines that disclosure is appropriate or required.

How much did lost businesses and licensing revenue affect Xtant's third-quarter 2026 sales?

The annual comparison included the absence of $5.4 million in prior-year revenue from divested Coflex/CoFix assets and the international hardware business, plus $5.5 million in prior-year wound care licensing revenue. HEMOBLAST revenue of $2.2 million partially offset those effects.

Keep reading